VCYT Q3 2017 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M-5.8% YoY

Gross Profit

$10M59.1% margin

Operating Income

-$6M-36.3% margin

Net Income

-$7M-40.2% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-4.8%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$84M

Total Liabilities

$41M

Stockholders' Equity

$43M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$19M	-5.8%
Gross Profit	$10M	$12M	-15.4%
Operating Income	-$6M	-$5M	-30.3%
Net Income	-$7M	-$6M	-25.0%